Overcoming Endocrine Resistance in Breast Cancer
Author:
Funder
National Cancer Institute
Publisher
Elsevier BV
Subject
Cancer Research,Cell Biology,Oncology
Reference194 articles.
1. Advances in endocrine-based therapies for estrogen receptor-positive metastatic breast cancer;Aggelis;Drugs,2019
2. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer;Alves;Breast Cancer Res.,2018
3. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer;Andre;N. Engl. J. Med.,2019
4. G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer;Andreano;Breast Cancer Res. Treat.,2020
5. The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies;Angus;Nat. Genet.,2019
Cited by 519 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. OBHSA, a novel selective estrogen receptor degrader, overcomes tamoxifen resistance through cell cycle arrest and unfolded protein response-mediated apoptosis in breast cancer;The Journal of Steroid Biochemistry and Molecular Biology;2024-11
2. Rational design of a poly-L-glutamic acid-based combination conjugate for hormone-responsive breast cancer treatment;Journal of Controlled Release;2024-11
3. Adipocyte-conditioned medium induces tamoxifen resistance by activating PI3K/Akt/mTOR pathway in estrogen receptor-positive breast cancer cells;Biochimica et Biophysica Acta (BBA) - Molecular Cell Research;2024-10
4. Current applications of tumor local ablation (TLA) combined with immune checkpoint inhibitors in breast cancer treatment;Cancer Drug Resistance;2024-09-13
5. Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer;Journal of Clinical Oncology;2024-09-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3